deferoxamine and Brain Diseases studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Brain Diseases: Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.

Research Excerpts

Excerpt	Relevance	Reference
" In the present study, we investigated the role of deferoxamine (DFO), as a clinical iron chelator, in improvement of type 1 diabetes-induced cognitive dysfunction."	7.96	Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. ( Nahavandi, A; Zare, M; Zeinivand, M, 2020)
"Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats."	7.75	Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Xi, G, 2009)
"Deferoxamine (DFO) has been widely used in the treatment of aluminum toxicity in patients on chronic dialysis."	5.28	[A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine]. ( Arizono, K; Fukui, H; Hayano, K; Miura, H; Otsuka, Y; Tajiri, M, 1989)
" In the present study, we investigated the role of deferoxamine (DFO), as a clinical iron chelator, in improvement of type 1 diabetes-induced cognitive dysfunction."	3.96	Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. ( Nahavandi, A; Zare, M; Zeinivand, M, 2020)
"Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats."	3.75	Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Xi, G, 2009)
" The metal chelator deferoxamine as well as three nitroxide derivatives, differing in hydrophilicity and charge, and one hydroxylamine (a reduced nitroxide) facilitated the clinical recovery and decreased the brain edema."	3.70	Mechanism of brain protection by nitroxide radicals in experimental model of closed-head injury. ( Bass, R; Beit-Yannai, E; Samuni, A; Shohami, E; Trembovler, V; Zhang, R, 1998)
" It is recommended to implement a stepwise increasing desferrioxamine dosage to prevent an acute decompensation with irreversible neurological lesions."	2.58	[Aluminic intoxication in chronic hemodialysis. A diagnosis rarely evoked nowadays. Clinical case and review of the literature]. ( Canaud, B; Dard, S; Drueke, T; Dupuis, E; Massy, ZA; Seidowsky, A, 2018)
"Aneurysmal subarachnoid hemorrhage (SAH) affects approximately 27,000 Americans per year."	1.36	Iron and early brain injury after subarachnoid hemorrhage. ( Loftspring, MC, 2010)
"Deferoxamine (DFO) has been widely used in the treatment of aluminum toxicity in patients on chronic dialysis."	1.28	[A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine]. ( Arizono, K; Fukui, H; Hayano, K; Miura, H; Otsuka, Y; Tajiri, M, 1989)
"Two patients with progressive dialysis encephalopathy (PDE) were subjected to serial EEG recording and neuropsychological tests in order to assess the value of the investigations as indices of the course of PDE during desferrioxamine treatment."	1.27	The EEG in progressive dialysis encephalopathy. The EEG and clinical indices of PDE in cases treated with desferrioxamine. (Part. II). ( Canavese, C; Luda, E; Rocca, G, 1984)
"Five patients with dialysis encephalopathy were transferred to deionized water; all died after a variable period, 4 of progressive dementia."	1.27	The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy. ( Bell, P; Meyers, AM; Milne, FJ; Sharf, B, 1983)

Research

Studies (37)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Number of Patients Who Died During the 90-day Study Period

Timeframe	Studies, this research(%)	All Research%
pre-1990	21 (56.76)	18.7374
1990's	11 (29.73)	18.2507
2000's	2 (5.41)	29.6817
2010's	2 (5.41)	24.3611
2020's	1 (2.70)	2.80

Authors	Studies
Zeinivand, M	1
Nahavandi, A	1
Zare, M	1
Seidowsky, A	1
Dupuis, E	1
Drueke, T	1
Dard, S	1
Massy, ZA	1
Canaud, B	1
Okauchi, M	1
Hua, Y	1
Keep, RF	1
Morgenstern, LB	1
Xi, G	1
Loftspring, MC	1
Ackrill, P	4
Ralston, AJ	2
Day, JP	4
Hodge, KC	1
Adhemar, JP	1
Laederich, J	1
Jaudon, MC	1
Masselot, JP	1
Galli, A	1
Kleinknecht, D	1
Arze, RS	1
Parkinson, IS	1
Cartlidge, NE	1
Britton, P	1
Ward, MK	1
Pogglitsch, H	1
Petek, W	1
Wawschinek, O	1
Holzer, W	1
Milne, FJ	2
Sharf, B	2
Bell, PD	1
Meyers, AM	2
Payton, CD	1
Junor, BJ	1
Fell, GS	1
Pierides, AM	1
Myli, MP	1
Luda, E	2
Canavese, C	2
Rocca, G	1
Bell, P	1
Kambova, L	1
Ionova, D	1
Kirijakov, Z	1
Savory, J	2
Herman, MM	1
Erasmus, RT	1
Boyd, JC	1
Wills, MR	1
Boelaert, JR	1
de Locht, M	1
Olivero, JJ	1
Lan, J	1
Jiang, DH	1
Zhang, R	1
Shohami, E	1
Beit-Yannai, E	1
Bass, R	1
Trembovler, V	1
Samuni, A	1
Tjalkens, RB	1
Ewing, MM	1
Philbert, MA	1
Ammon, A	1
Rumpf, KW	1
Hommerich, CP	1
Behrens-Baumann, W	1
Rüchel, R	1
Anand, VK	1
Alemar, G	1
Griswold, JA	1
Wens, R	1
Devriendt, J	1
Collart, F	1
Dratwa, M	1
Bisschop, P	1
Telerman-Toppet, N	1
Douat, N	1
Ellenberg, R	1
King, AL	1
Sica, DA	1
Posner, M	1
Lillevang, ST	1
Pedersen, FB	1
Arizono, K	1
Fukui, H	1
Miura, H	1
Hayano, K	1
Otsuka, Y	1
Tajiri, M	1
Rovelli, E	1
Luciani, L	1
Pagani, C	1
Albonico, C	1
Colleoni, N	1
D'Amico, G	1
Coburn, JW	1
Norris, KC	1
Sherrard, DJ	1
Bia, M	1
Llach, F	1
Alfrey, AC	1
Slatopolsky, E	1
Starkstein, S	1
Berthier, M	1
Nogués, M	1
Leiguarda, R	1
Lewis, M	1
Lesniak, S	1
Mudde, AH	1
Roodvoets, AP	1
Van Groningen, K	1
Dooling, EC	1
Schoene, WC	1
Richardson, EP	1
Gallyas, F	1
Környey, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage[NCT02367248]	Phase 1/Phase 2	180 participants (Anticipated)	Interventional	2015-03-31	Recruiting
Futility Study of Deferoxamine in Intracerebral Hemorrhage[NCT01662895]	Phase 2	42 participants (Actual)	Interventional	2013-03-18	Terminated (stopped due to By DSMB on October 18, 2013 due to increased incidence of ARDS. See modified protocol [NCT02175225)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Mortality at any time from randomization through day-90 (NCT01662895)
Timeframe: 90 days

Number of Patients With Hypotension

Number of Patients With New Visual or Auditory Changes

Number of Patients With Serious Adverse Events

Number of Subjects With Acute Respiratory Distress Syndrome

Number of Subjects With Allergic/Anaphylactic Reaction

Number of Subjects With Modified Rankin Scale (mRS) Score 0-2

Intervention	Participants (Count of Participants)
Deferoxamine	3
Normal Saline	0

Intervention	Participants (Count of Participants)
Deferoxamine	1
Normal Saline	1

Intervention	Participants (Count of Participants)
Deferoxamine	0
Normal Saline	1

Intervention	Participants (Count of Participants)
Deferoxamine	9
Normal Saline	6

Intervention	Participants (Count of Participants)
Deferoxamine	6
Normal Saline	0

Intervention	Participants (Count of Participants)
Deferoxamine	0
Normal Saline	0

"The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.~The minimum mRS score is 0 (i.e. no disability). The maximum score is 6 (i.e. dead)." (NCT01662895)
Timeframe: 90 days

Number of Subjects With mRS Score 0-3

Intervention	Participants (Count of Participants)
Deferoxamine	6
Normal Saline	10

The proportion of DFO- and placebo-treated subjects with mRS 0-3 vs. 4-6 at 90 days (NCT01662895)
Timeframe: 90 days

Article	Year
[Aluminic intoxication in chronic hemodialysis. A diagnosis rarely evoked nowadays. Clinical case and review of the literature]. Nephrologie & therapeutique, 2018, Volume: 14, Issue:1 Topics: Aluminum; Brain Diseases; Deferoxamine; Electrocardiography; Humans; Kidney Failure, Chronic; Male;	2018
The use of desferrioximine in dialysis-associated aluminium disease. Contributions to nephrology, 1993, Volume: 102 Topics: Aluminum; Anemia; Bone Diseases; Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Rena	1993
Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. Journal of neural transmission (Vienna, Austria : 1996), 1997, Volume: 104, Issue:4-5 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Disease	1997
Intracranial complications of mucormycosis: an experimental model and clinical review. The Laryngoscope, 1992, Volume: 102, Issue:6 Topics: Adult; Alloxan; Amphotericin B; Animals; Brain Abscess; Brain Diseases; Child; Deferoxamine; Diabete	1992

Article	Year
Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. Inflammopharmacology, 2020, Volume: 28, Issue:2 Topics: Animals; Avoidance Learning; Brain Diseases; Cognitive Dysfunction; Deferoxamine; Diabetes Mellitus,	2020
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. Stroke, 2009, Volume: 40, Issue:5 Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases;	2009
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. Stroke, 2009, Volume: 40, Issue:5 Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases;	2009
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. Stroke, 2009, Volume: 40, Issue:5 Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases;	2009
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. Stroke, 2009, Volume: 40, Issue:5 Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases;	2009
Iron and early brain injury after subarachnoid hemorrhage. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2010, Volume: 30, Issue:11 Topics: Animals; Brain Diseases; Deferoxamine; DNA Damage; Humans; Iron; Iron Chelating Agents; Oxidative St	2010
Successful removal of aluminium from patient with dialysis encephalopathy. Lancet (London, England), 1980, Sep-27, Volume: 2, Issue:8196 Topics: Adult; Aluminum; Brain; Brain Diseases; Deferoxamine; Hemodialysis, Home; Humans; Male	1980
Removal of aluminium from patients with dialysis encephalopathy. Lancet (London, England), 1980, Dec-13, Volume: 2, Issue:8207 Topics: Adult; Aged; Aluminum; Blood; Brain Diseases; Deferoxamine; Humans; Renal Dialysis; Ultrafiltration	1980
Reversal of aluminium dialysis encephalopathy after desferrioxamine treatment. Lancet (London, England), 1981, Nov-14, Volume: 2, Issue:8255 Topics: Aluminum; Brain Diseases; Deferoxamine; Humans; Male; Renal Dialysis; Water Supply	1981
Treatment of early stages of dialysis encephalopathy by aluminium depletion. Lancet (London, England), 1981, Dec-12, Volume: 2, Issue:8259 Topics: Aluminum; Apraxias; Brain Diseases; Deferoxamine; Dysarthria; Humans; Male; Renal Dialysis	1981
Low aluminium water, desferrioxamine, and dialysis encephalopathy. Lancet (London, England), 1982, Aug-28, Volume: 2, Issue:8296 Topics: Aluminum; Brain Diseases; Deferoxamine; Humans; Renal Dialysis; Water Supply	1982
Successful treatment of aluminium encephalopathy by intraperitoneal desferrioxamine. Lancet (London, England), 1984, May-19, Volume: 1, Issue:8386 Topics: Aluminum; Brain Diseases; Deferoxamine; Female; Humans; Injections, Intraperitoneal; Middle Aged; Pe	1984
Therapy of aluminum overload (I). Contributions to nephrology, 1984, Volume: 38 Topics: Adult; Aged; Aluminum; Bone and Bones; Brain Diseases; Deferoxamine; Female; Humans; Kidney Failure,	1984
The EEG in progressive dialysis encephalopathy. The EEG and clinical indices of PDE in cases treated with desferrioxamine. (Part. II). Italian journal of neurological sciences, 1984, Volume: 5, Issue:4 Topics: Aluminum; Brain Diseases; Deferoxamine; Electroencephalography; Humans; Middle Aged; Neuropsychologi	1984
EEG study on progressive dialytic encephalopathy in treatment with desferrioxamine. The International journal of artificial organs, 1983, Volume: 6, Issue:4 Topics: Brain Diseases; Deferoxamine; Electroencephalography; Humans; Renal Dialysis	1983
The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy. Clinical nephrology, 1983, Volume: 20, Issue:4 Topics: Adult; Aged; Aluminum; Bone Diseases; Brain Diseases; Deferoxamine; Dementia; Electroencephalography	1983
Therapy of aluminium overload (II). Contributions to nephrology, 1984, Volume: 38 Topics: Aluminum; Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Osteomalacia; Renal Dialysi	1984
Aluminium overload influences cognitive function in patients on dialysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1994, Volume: 9, Issue:9 Topics: Adult; Aluminum; Brain Diseases; Chelating Agents; Cognition; Deferoxamine; Female; Humans; Male; Mi	1994
Partial reversal of aluminium-induced neurofibrillary degeneration by desferrioxamine in adult male rabbits. Neuropathology and applied neurobiology, 1994, Volume: 20, Issue:1 Topics: Aluminum Compounds; Animals; Brain Diseases; Deferoxamine; Histocytochemistry; Injections, Intravent	1994
Side-effects of desferrioxamine in dialysis patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1993, Volume: 8 Suppl 1 Topics: Bacterial Infections; Brain Diseases; Deferoxamine; Eye; Hearing Loss, Sensorineural; Humans; Iron;	1993
Hemoptysis and altered sensorium in a hemodialysis patient. Hospital practice (Office ed.), 1993, Mar-30, Volume: 28, Issue:3A Topics: Aluminum; Aluminum Hydroxide; Brain Diseases; Deferoxamine; Hemoptysis; Humans; Kidney Failure, Chro	1993
Mechanism of brain protection by nitroxide radicals in experimental model of closed-head injury. Free radical biology & medicine, 1998, Jan-15, Volume: 24, Issue:2 Topics: Animals; Antioxidants; Blood-Brain Barrier; Brain Diseases; Brain Edema; Deferoxamine; Head Injuries	1998
Differential cellular regulation of the mitochondrial permeability transition in an in vitro model of 1,3-dinitrobenzene-induced encephalopathy. Brain research, 2000, Aug-25, Volume: 874, Issue:2 Topics: Adenosine Triphosphate; Antioxidants; bcl-2-Associated X Protein; bcl-X Protein; Brain Diseases; Cal	2000
[Rhinocerebral mucormycosis during deferoxamine therapy]. Deutsche medizinische Wochenschrift (1946), 1992, Sep-18, Volume: 117, Issue:38 Topics: Adult; Blindness; Brain Diseases; Cellulitis; Combined Modality Therapy; Deferoxamine; Female; Human	1992
Rhinocerebral mucormycosis in haemodialysis patients treated with desferrioxamine: possible role of recent surgery as an additional risk factor. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1991, Volume: 6, Issue:9 Topics: Amphotericin B; Brain Diseases; Deferoxamine; Humans; Male; Middle Aged; Mucormycosis; Nasal Mucosa;	1991
Cerebrospinal fluid aluminum levels following deferoxamine. American journal of kidney diseases : the official journal of the National Kidney Foundation, 1990, Volume: 16, Issue:2 Topics: Adult; Aluminum; Brain Diseases; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Kidney Trans	1990
Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1989, Volume: 4, Issue:7 Topics: Aluminum; Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Di	1989
[A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine]. Nihon Jinzo Gakkai shi, 1989, Volume: 31, Issue:1 Topics: Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mucormycosis; Rena	1989
Correlation between serum aluminum concentration and signs of encephalopathy in a large population of patients dialyzed with aluminum-free fluids. Clinical nephrology, 1988, Volume: 29, Issue:6 Topics: Aluminum; Brain Diseases; Deferoxamine; Electroencephalography; Female; Humans; Male; Middle Aged; N	1988
Toxic effects of aluminum in end-stage renal disease: discussion of a case. American journal of kidney diseases : the official journal of the National Kidney Foundation, 1988, Volume: 12, Issue:3 Topics: Aluminum; Bone Diseases, Metabolic; Brain Diseases; Deferoxamine; Female; Hemodialysis, Home; Humans	1988
Role of desferrioxamine in the treatment of dialysis encephalopathy. Kidney international. Supplement, 1986, Volume: 18 Topics: Adult; Aged; Aluminum; Brain Diseases; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Male;	1986
[Treatment of dialysis encephalopathy with deferoxamine]. Medicina, 1986, Volume: 46, Issue:3 Topics: Adult; Aluminum Hydroxide; Brain Diseases; Deferoxamine; Electroencephalography; Humans; Male; Renal	1986
Deferoxamine use in aluminum toxicity. ANNA journal, 1986, Volume: 13, Issue:4 Topics: Aluminum; Brain Diseases; Deferoxamine; Female; Humans; Middle Aged; Renal Dialysis	1986
Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine. The Netherlands journal of medicine, 1985, Volume: 28, Issue:1 Topics: Aluminum Hydroxide; Brain Diseases; Deferoxamine; Female; Humans; Hypercalcemia; Male; Middle Aged;	1985
Hallervorden-Spatz syndrome. Archives of neurology, 1974, Volume: 30, Issue:1 Topics: Adult; Amantadine; Autopsy; Brain; Brain Diseases; Cerebral Cortex; Deferoxamine; Electroencephalogr	1974
[A further contribution to the knowledge of the Hallervorden-Spatz disease]. Archiv fur Psychiatrie und Nervenkrankheiten, 1968, Volume: 212, Issue:1 Topics: Adolescent; Brain Diseases; Deferoxamine; Globus Pallidus; Humans; Iron; Iron Isotopes; Male; Molecu	1968

deferoxamine and Brain Diseases